HsuYPHsuCWBaiCHChengSWChenC. Medical treatment for epistaxis in hereditary hemorrhagic telangiectasia: a meta-analysis [published online September11, 2018]. Otolaryngol Head Neck Surg. doi:10.1177/0194599818797316
2.
Al-SamkariHKritharisARodriguez-LopezJMKuterDJ. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia [published online September6, 2018]. J Intern Med. doi:10.1111/joim.12832
3.
Dupuis-GirodSGinonISaurinJCet al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA. 2012;307:948-955.
4.
GuilhemAFargetonAESimonACet al. Intravenous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): a retrospective study of 46 patients. PLoS One. 2017;12:e0188943.
5.
IyerVNApalaDRPannuBSet al. Intravenous bevacizumab for refractory hereditary hemorrhagic telangiectasia-related epistaxis and gastrointestinal bleeding. Mayo Clin Proc. 2018;93:155-166.
